Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaBiographical Sketch:
Dr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She is specialized in the treatment of breast cancer.
After completing her master of science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series. She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients’ access to healthcare, as well as community collaborations for education and advocacy.
Positions:
Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida
Degrees:
DO: University of New England College of Osteopathic Medicine
MS (Neuroscience): University of Connecticut
Postgraduate Training:
Fellowship: St. Vincent’s Catholic Medical Center, New York, New York
Certificate:
Harvard Global Clinical Scholars Training Program
Clinical Interests:
Breast cancer, novel therapeutics
Disclosures
Reshma L. Mahtani, DO, has served as a consultant/advisor for Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline, SeaGen.
Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Fasting Glucose and BMI Predict Activity in Breast Cancer Patients Treated With Everolimus-Exemestane
- Durable Complete Response in HER2-Positive Breast Cancer Following Trastuzumab Discontinuation
- A Contextual Review of New Data on CDK 4/6 Inhibitors
- ESMO 2017: Recommendations From Dr. Reshma Mahtani
- Neratinib Efficacy and ctDNA Detection of HER2 Mutations in HER2 Non-Amplified Metastatic Breast Cancer
- Primary Metastatic Breast Cancer in the Era of Targeted Therapy—Prognostic Impact and the Role of Breast Tumor Surgery
- Efficacy of Targeted Agents in Combination With Chemotherapy for Advanced Triple-Negative Breast Cancer
- Ixabepilone and Carboplatin for HR+ and Triple-Negative Metastatic Breast Cancer
- Patients Prefer Subcutaneous Trastuzumab Administration in HER2-Positive Metastatic Breast Cancer
- First Report of Eribulin in Combination With Pertuzumab and Trastuzumab for Advanced HER2-Positive Breast Cancer